NewLink Genetics Corporation (NewLink) is a late-stage, biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Our portfolio includes both “off-the-shelf” biologic and small-molecule immunotherapy product candidates intended to address large, unmet oncology indications, including treatment of pancreatic cancer, non-small cell lung cancer (NSCLC), and melanoma. We believe our technologies may also be useful in the field of infectious disease.
Our biologic pipeline is based on NewLink’s HyperAcute® technology platform, which is designed to harness multiple components of the innate immune system to combat cancer, either alone or in combination with other treatments, without significant incremental toxicity. In contrast to autologous therapies, HyperAcute product candidates do not require patients to donate cellular material, which permits an easier scale-up of the manufacturing process. To date, HyperAcute product candidates have been administered to more than 350 cancer patients and have demonstrated good tolerability and a favorable safety profile.
2503 S. Loop Drive, Suite 5100
Ames, IA 50010